BACKGROUND: An increasing promising evidence and increasing long-term oncologic outcomes support the use of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) as locoregional treatment for peritoneal carcinosis (PC) especially from ovarian and gastrointestinal tumors, but also for others cancers. METHODS: A prospective monocentric study was performed in Papa Giovanni XXIII Hospital, Bergamo (Italy). Patients and tumor characteristics were analyzed. Overall survival (OS), disease free survival (DFS) and morbidity were analyzed with Kaplan-Meier curves and log-rank testing. RESULTS: A total of 150 patients undergone CRS + HIPEC were analyzed from January 2011 to June 2017. The principal origins of PC were: gastric cancer (GC) (n=40), colon cancer (n=31), appendiceal cancer (AC) (n=18), ovarian cancer (OC) (n=49), others (n=12). Major morbidity [≥3 Common Terminology Criteria for Adverse Events (CTCAE)] and perioperative mortality rates were 38% and 2.7% respectively. Re-operation rate was 15.3%. Median OS is 9, 35, 47, 51, 82 months (29% 3-year OS; 27% 5-year OS; 48% 5-year OS; 40% 5-year OS; 67% 5-year OS respectively) in GC, colorectal cancer (CRC), OC, others tumors and AC respectively. Median DFS is 4, 14, 17, 19, 82 months (32% 3-year DFS; 22% 5-year DFS; 29% 5-year DFS; 11% 5-year DFS; 67% 5-year DFS respectively) in GC, CRC, others tumors, OC and AC respectively. CONCLUSIONS: A therapeutic approach that combined CRS + HIPEC could achieve long-term survival in selected groups of patients with PC from gastrointestinal, gynecological and others tumors with acceptable morbidity and mortality. A good expertise and a high volume of patients are necessary to manage PC and to further improve results.
BACKGROUND: An increasing promising evidence and increasing long-term oncologic outcomes support the use of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) as locoregional treatment for peritoneal carcinosis (PC) especially from ovarian and gastrointestinal tumors, but also for others cancers. METHODS: A prospective monocentric study was performed in Papa Giovanni XXIII Hospital, Bergamo (Italy). Patients and tumor characteristics were analyzed. Overall survival (OS), disease free survival (DFS) and morbidity were analyzed with Kaplan-Meier curves and log-rank testing. RESULTS: A total of 150 patients undergone CRS + HIPEC were analyzed from January 2011 to June 2017. The principal origins of PC were: gastric cancer (GC) (n=40), colon cancer (n=31), appendiceal cancer (AC) (n=18), ovarian cancer (OC) (n=49), others (n=12). Major morbidity [≥3 Common Terminology Criteria for Adverse Events (CTCAE)] and perioperative mortality rates were 38% and 2.7% respectively. Re-operation rate was 15.3%. Median OS is 9, 35, 47, 51, 82 months (29% 3-year OS; 27% 5-year OS; 48% 5-year OS; 40% 5-year OS; 67% 5-year OS respectively) in GC, colorectal cancer (CRC), OC, others tumors and AC respectively. Median DFS is 4, 14, 17, 19, 82 months (32% 3-year DFS; 22% 5-year DFS; 29% 5-year DFS; 11% 5-year DFS; 67% 5-year DFS respectively) in GC, CRC, others tumors, OC and AC respectively. CONCLUSIONS: A therapeutic approach that combined CRS + HIPEC could achieve long-term survival in selected groups of patients with PC from gastrointestinal, gynecological and others tumors with acceptable morbidity and mortality. A good expertise and a high volume of patients are necessary to manage PC and to further improve results.
Entities:
Keywords:
Peritoneal carcinosis (PC); appendiceal cancer (AC); colorectal cancer; cytoreductive surgery (CRS); gastric cancer (GC); hyperthermic intraperitoneal chemotherapy (HIPEC); others tumors; ovarian cancer (OC)
Authors: F Coccolini; F Catena; O Glehen; Y Yonemura; P H Sugarbaker; P Piso; G Montori; L Ansaloni Journal: Eur J Surg Oncol Date: 2015-04-14 Impact factor: 4.424
Authors: Reza Mirnezami; Brendan J Moran; Kate Harvey; Tom Cecil; Kandiah Chandrakumaran; Norman Carr; Faheez Mohamed; Alexander H Mirnezami Journal: World J Gastroenterol Date: 2014-10-14 Impact factor: 5.742
Authors: Charlotte E L Klaver; Gijsbert D Musters; Willem A Bemelman; Cornelis J A Punt; Victor J Verwaal; Marcel G W Dijkgraaf; Arend G J Aalbers; Jarmila D W van der Bilt; Djamila Boerma; Andre J A Bremers; Jacobus W A Burger; Christianne J Buskens; Pauline Evers; Robert J van Ginkel; Wilhelmina M U van Grevenstein; Patrick H J Hemmer; Ignace H J T de Hingh; Laureen A Lammers; Barbara L van Leeuwen; Wilhelmus J H J Meijerink; Simon W Nienhuijs; Jolien Pon; Sandra A Radema; Bert van Ramshorst; Petur Snaebjornsson; Jurriaan B Tuynman; Elisabeth A Te Velde; Marinus J Wiezer; Johannes H W de Wilt; Pieter J Tanis Journal: BMC Cancer Date: 2015-05-24 Impact factor: 4.430